Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224

Core Insights - Krystal Biotech, Inc. (NASDAQ:KRYS) is recognized as a leading gene therapy stock by hedge funds, with Guggenheim raising its price target from $224 to $284 while maintaining a Buy rating after the company's fiscal Q4 report [1] - The company reported VYJUVEK net product revenues of $107.1 million for fiscal Q4 and $389.1 million for the full year 2025 [1] - Krystal Biotech has secured over 660 reimbursement approvals for VYJUVEK in the U.S. and is experiencing strong uptake in Germany, France, and Japan, with over 90 patients prescribed the therapy [2] Financial Performance - For fiscal Q4, Krystal Biotech reported net product revenue of $107.1 million, while the full year 2025 revenue reached $389.1 million [1] - The company ended the quarter with a robust balance sheet, holding $955.9 million in cash and investments [2] Product and Market Development - VYJUVEK is a topical gel designed to treat wounds in patients with dystrophic epidermolysis bullosa (DEB) [3] - The company is in discussions regarding pricing with reimbursement authorities in Italy, aiming for a potential launch in the second half of 2026 [2]